Last Day of @asco#GU26
Proud to see @Nora_Sobrevilla 🇲🇽 from @incanMX as chair of #kidneycancer case discussions today!!
Awaiting to see how practice decisions have changed after this meeting data!!
LAST DAY!! #GU26@asco 📅
⏰Awaiting @katy_beckermann discussion of the LITESPARK studies! starting 8:10 am
- Are we going to change treatment sequencing in mRCC? @motzermd
- Is there a new standard for adjuvant ccRCC? @DrChoueiri
Don´t miss this evvent @Larvol@OncoAlert
DAY3⃣ @asco#GU26#kidneycancer The BELZUTIFAN story!
🔴LITESPARK-011 Belzu + lenva vs cabo for aRCC after PDL1
🔵LITESPARK-022 Adjuvant pembro+belzu vs pembro in localized ccRCC @DrChoueiri
🟠LITESPARK-024 dose escalation of belzu + palbo
#ASCOVoices@OncoAlert@oncodaily
DAY 1 #prostatecancer news this PM @ASCO#GU26
🛑 PEACE 2: ADT+ RT +/- cabazitaxel in very high-risk localized PCa
📈 P1 escalation studies: VIR-5500 (AMX-500) a dual T-cell engager targeting PSMA & actinium-225-PSMA in mCRPC
🎉 PSMAddition: QOL w Lu-PSMA-617 mHSPC
@OncoAlert
Day 1: Prostate 8:15 am @ASCO#GU26
3️⃣ studies w updated OS
✅ PEACE 3: enza w or w/o radium-223 in mCRPC
✅ BRCAway: abi vs Olaparib vs abi+Olaparib mCRPC & DNA repair def
✅ ASCENDE-RT ⏩ 15 years external beam RT boost vs brachy in localized PC
@OncoAlert@UrologyTimes